Publication

Retinopathy as a possible side effect in the subcutaneous treatment with interferon-beta

Presentation - Apr 1, 2008

Units
Keywords
interferon-beta, retinopathy, side effect

Citation
Vehoff J (2008). Retinopathy as a possible side effect in the subcutaneous treatment with interferon-beta. Presented at: 100 Jahre SNG Jubiläumstagung Schweizerische Neurologische Gesellschaft SNG, Montreux, Schweiz
Type
Presentation (English)
Event Name
100 Jahre SNG Jubiläumstagung Schweizerische Neurologische Gesellschaft SNG (Montreux, Schweiz)
Publication Date
Apr 1, 2008
Brief description/objective

A 44-year-old female, diagnosed with relapsing remitting MS, started a disease-modifying therapy (DMT) with interferon-beta 1a (Rebif® 44 μg/3 times weekly) in 08/06. One and a half month later, the patient claimed decreased visual function on both eyes. An ophthalmologic examination showed few retinal cotton-wool spots hich rapidly increased until 11/06. As no other explanation for the retinopathy was found, a casual relationship between the DMT and the retinopathy was suspected and Rebif® was stopped. One and a half month later, a complete remission of the cotton-wool spots was observed. Another DMT, this time interferonbeta 1b (Betaferon®), as begun in 02/07. One month later, the ophthalmologic control showed no signs of retinopathy at all. Shortly after this examination, he patient complained of the same visual symptoms as during Rebif® therapy. Again severe bilateral retinopathy with cotton-wool pots was found and the DMT was stopped. During follow-up a slow improvement of the retinopathy was observed. Retinopathy secondary to treatment with interferon is well known in the reatment with interferon-alpha. Despite being a frequently occurring complication, it is usually a mild condition and disappears when withdrawing the treatment, or even if therapy is continued.
Only few cases associated with the treatment with interferon-beta have been reported in the literature so far.We recommend thinking of this possible side effect when treating MS patients with interferon-beta.